← Eichor
Study identifier: NCT07519486 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC

Condition: Esophageal Squamous Cell Carcinoma · Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma  ·  Sponsor: Sichuan University

PhasePhase 2
Planned participants118
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Malnutrition is highly prevalent in patients with upper gastrointestinal tumors, which may negatively impact treatment tolerance and anti-tumor immune responses. This study aims to evaluate the efficacy and safety of intensive enteral nutritional support in patients with locally advanced unresectable esophageal squamous cell carcinoma (ESCC) undergoing conversion therapy. Participants receiving PD-1 inhibitors combined with chemotherapy will be randomly assigned to either intensive nutritional support or standard care. The primary goal is to determine if intensive nutritional support can improve the pathological complete response (pCR) rate after subsequent surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Zhenyu Ding, PhD  ·  +86-189-8060-1957  ·  dingzhenyu@scu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

West China Hospital, Sichuan UniversityChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07519486